Publish date:

Alnylam Posts Wider Loss

The biotech, however, raises its year-end 2007 cash guidance.

RNAi therapeutics company

Alnylam Pharmaceuticals

(ALNY) - Get Alnylam Pharmaceuticals, Inc Report

reported a widened second-quarter loss late Thursday but upped year-end cash estimates.

Alnylam recorded a net loss of $12.7 million, or 34 cents a share, compared with $9.9 million, or 31 cents a share, in the year-prior period. That's including a 5-cent-per-share stock-based compensation expense in both quarters.

Analysts surveyed by Thomson Financial had expected a loss of 24 cents a share on revenue of $7.1 million.

Alnylam reported revenue of $9.1 million, compared with $6 million during the year-ago quarter. This year's revenue included $4.4 million related to Alnylam's collaborations with


(NVS) - Get Novartis AG Sponsored ADR Report

, $2.8 million from the National Institutes of Health for Ebola, and $1.9 million of expense reimbursement and amortization revenues from

TheStreet Recommends

Biogen Idec

(BIIB) - Get Biogen Inc. Report



(MRK) - Get Merck & Co., Inc. (MRK) Report

, research reagent and services licensees, and other sources.

The company increased its year-end 2007 cash guidance to greater than $435 million from greater than $180 million to reflect its alliance with


. Alnylam also announced that it has completed the previously announced

deal with the Swiss drugmaker.

The company's shares closed up 2.1% at $25.98 and rose another 0.9% to $26.20 in postmarket trading.